KLK3 and Familial prostate cancer: The use of the N/L ratio did not fulfill these requirements and did not discriminate between patients with clinically significant prostate cancer, indolent cancer and benign prostatic disease in a Chilean screening population with a PSA of 4-10 ng/ml.